Approved indications (U.S.): Ursodiol is approved for: (1) dissolution of small, non‑calcified, radiolucent cholesterol gallstones in patients who are not surgical candidates, and (2) treatment of primary biliary cholangitis (primary biliary cirrhosis) in adults to improve liver tests and delay disease progression.

Off‑label uses and evidence: Clinicians may use ursodiol off‑label in certain cholestatic liver diseases (e.g., intrahepatic cholestasis of pregnancy, some pediatric cholestatic disorders) and after liver transplantation; evidence ranges from moderate (clinical trials and cohort studies) to limited (small series or expert opinion) depending on the condition.

Efficacy expectations: For gallstone dissolution, improvement is slow—partial response may be seen in a few months and complete dissolution, if it occurs, usually takes 6–24 months and is less likely with large or calcified stones; stones can recur after stopping therapy. For primary biliary cholangitis, liver blood tests often start to improve within 3–6 months, and long‑term use is associated with slower progression, better symptom control in many patients, and improved transplant‑free survival compared with no ursodiol. Compared with no bile‑acid therapy, ursodiol is standard first‑line treatment for PBC; other agents such as obeticholic acid or fibrates are typically added or substituted when response to ursodiol alone is inadequate.

Typical dosing and how to take: For primary biliary cholangitis, dosing is usually about 13–15 mg/kg/day by mouth, divided into 2–4 doses with food. For gallstone dissolution, dosing is often around 8–10 mg/kg/day, usually given in 2–3 divided doses with meals at consistent times each day. Capsules and tablets should be swallowed whole with water, unless a specific liquid or compounded form is prescribed.

Special dosing instructions: Dosing is based on body weight; clinicians may adjust the dose according to response and liver tests. It may take many months to see full benefit, so doses should not be changed or stopped without medical advice. Patients with significant liver dysfunction or other serious conditions need individualized dosing and close follow‑up.

Missed dose guidance: If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; in that case, skip the missed dose and resume the regular schedule. Do not double doses to make up for a missed one.

Overdose: Taking more than prescribed can increase gastrointestinal side effects such as diarrhea and potentially affect liver function; if an overdose is suspected, contact a poison control center or emergency medical services right away and bring a list of all medications taken.

Common side effects: The most frequent effects are diarrhea or looser stools, constipation, abdominal discomfort, nausea, and sometimes headache or dizziness; these are usually mild to moderate, may appear in the first days to weeks of therapy, and often improve with continued use or dose adjustment.

Serious or rare adverse effects: Worsening liver test results, severe right‑upper‑abdominal pain, signs of acute gallbladder problems (such as fever, jaundice, intense abdominal pain), or signs of allergic reaction (rash, swelling, trouble breathing) are uncommon but require immediate medical attention. In advanced liver disease with decompensation, inappropriate use or dose may be harmful.

Warnings and precautions: Use caution in people with complete biliary obstruction or active acute cholecystitis or cholangitis, where ursodiol is generally not appropriate. In pregnancy, ursodiol is widely used and generally considered relatively safe when clearly indicated (for example, intrahepatic cholestasis of pregnancy), but decisions should be individualized. Small amounts are expected to pass into breast milk; most data suggest low risk, but nursing patients should discuss risks and benefits with their clinician. Dose adjustments or close monitoring may be needed in significant liver disease, and ursodiol is not useful if the liver is already severely decompensated.

Relative safety profile: Compared with many other hepatobiliary drugs, ursodiol has a relatively favorable safety profile when used at recommended doses and with proper selection of patients, though it is not risk‑free.

Side‑effect reporting and safety updates: Patients in the United States can report suspected side effects to the FDA’s MedWatch program and can review current safety communications and prescribing information through the FDA website or the manufacturer’s medication guide.

Drug and supplement interactions: Bile‑acid binding resins (such as cholestyramine, colestipol, or colesevelam) and some aluminum‑containing antacids can reduce absorption of ursodiol and should usually be taken several hours apart. Certain cholesterol‑lowering drugs, estrogen therapy, and some hormonal contraceptives may increase cholesterol in bile and counteract gallstone dissolution. Always review over‑the‑counter medications and herbal supplements with a clinician, as data on many supplements are limited.

Food, alcohol, and procedure interactions: Ursodiol is typically taken with food to improve absorption and reduce stomach upset. Moderate alcohol intake should be discussed with a clinician, especially in people with any liver disease, because alcohol itself can worsen liver damage. There are no specific known interactions with imaging contrast agents, but liver tests and imaging results should be interpreted in the context of ursodiol therapy.

Precautions and contraindications: Ursodiol is generally avoided in complete biliary obstruction, acute inflammation of the gallbladder or bile ducts, and in patients with radiopaque or calcified gallstones that are unlikely to respond. Careful evaluation is needed in people with advanced cirrhosis, severe pancreatitis, or other serious gastrointestinal conditions.

Monitoring needs: For liver diseases such as primary biliary cholangitis, regular blood tests (liver function tests, sometimes bilirubin and alkaline phosphatase) are recommended to assess response and detect potential toxicity. Periodic imaging (e.g., gallbladder ultrasound) may be used during gallstone dissolution therapy to check stone size and number and to decide whether treatment should continue.

Q: How long does it take for ursodiol to work for gallstones?
A: Gallstone dissolution is slow; some people see partial improvement within a few months, but complete dissolution, when it occurs, typically takes 6–24 months and is less likely with larger or calcified stones.

Q: Will I need to take ursodiol for the rest of my life for primary biliary cholangitis?
A: Many patients with primary biliary cholangitis stay on ursodiol long term or indefinitely because continuous use helps keep liver tests improved and slows disease progression; your specialist will periodically reassess your need for ongoing treatment.

Q: Can I drink alcohol while taking ursodiol?
A: Small amounts of alcohol may be allowed for some patients, but because alcohol can worsen liver damage, you should ask your clinician what level, if any, is safe in your specific situation.

Q: What happens if I miss a dose of ursodiol?
A: Take the missed dose as soon as you remember unless it is almost time for your next scheduled dose; if so, skip the missed dose and resume your usual schedule without doubling up.

Q: Do gallstones come back after stopping ursodiol?
A: Yes, gallstones can recur once ursodiol is stopped, especially if the underlying risk factors for stone formation remain, which is why clinicians carefully select candidates and may recommend other treatments when appropriate.

Storage: Keep ursodiol at room temperature in a tightly closed container, protected from excessive heat and moisture, and out of reach of children and pets.

Disposal: Do not flush capsules or tablets down the toilet unless instructed; use a local medication take‑back program or follow pharmacy/municipal guidance for mixing unused pills with undesirable trash (such as used coffee grounds or cat litter) in a sealed bag before discarding.